EnPlusOne Biosciences focuses on innovative biopharmaceutical solutions, particularly in the realm of protein engineering and therapeutic development. The company employs advanced technologies to enhance the efficacy and safety of biologics, including monoclonal antibodies and other protein-based therapeutics. Their proprietary platform allows for the optimization of protein structures, enabling the development of more effective treatments for various diseases, including cancer and autoimmune disorders. This approach not only improves the therapeutic potential of existing drugs but also facilitates the discovery of novel biologics.

In addition to protein engineering, EnPlusOne Biosciences leverages cutting-edge techniques in drug formulation and delivery systems. Their research emphasizes the importance of bioavailability and targeted delivery, ensuring that therapeutic agents reach their intended sites of action with maximum efficiency. By integrating these technologies, the company aims to address significant challenges in drug development, ultimately leading to improved patient outcomes and a more streamlined path from research to clinical application.

United States

EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com

EnPlusOne Biosciences

Company Details